|
May 5
|
Earnings Beat: Castle Biosciences, Inc. (NASDAQ:CSTL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
|
|
May 5
|
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript
|
|
May 3
|
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
|
|
May 2
|
Castle Biosciences Inc (CSTL) Q1 2024 Earnings: Surpasses Revenue Forecasts and Raises Annual ...
|
|
May 2
|
Castle Biosciences Reports First Quarter 2024 Results
|
|
Apr 30
|
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
|
|
Apr 17
|
We're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash Burn
|
|
Apr 11
|
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
|
|
Apr 10
|
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
|
|
Apr 10
|
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
|
|
Apr 5
|
What Makes Castle Bioscience (CSTL) a Prospective Investment?
|
|
Apr 4
|
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
|
|
Apr 2
|
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 27
|
Castle Biosciences Announces Updates to its Board of Directors
|
|
Mar 25
|
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
|
|
Mar 22
|
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
|
|
Mar 20
|
Does Castle Bioscience (CSTL) Have Robust Growth Prospects?
|
|
Mar 19
|
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
|
|
Mar 15
|
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
|
|
Mar 12
|
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
|